Stock-Based Compensation

3 Months Ended

Mar. 31, 2023

Share-Based Payment Arrangement [Abstract]

The Human Resources and Compensation Committee of our Board of Directors granted 519,482 stock options, 665,417 restricted stock units (“RSUs”) and 542,743 performance stock units (“PSUs”), and our electing non-employee directors received 30,441 deferred share units (“DSUs”) during the three months ended March 31, 2023 under our Omnibus Equity Incentive Plan. The weighted average exercise price per share and weighted average fair value per share of the stock options granted in the three months ended March 31, 2023 was $5.51 and $3.01, respectively. We estimated the fair value of the stock options using the following assumptions in our Black-Scholes model:

Dividend yield

0.73%

Expected volatility

58.16%

Risk-free interest rate

4.04%

Expected term (in years)

6.0 years

We measure the fair value of grants of RSUs and DSUs based on the closing market price of a share of our common stock on the date of the grant. The weighted average fair value per share was $5.58 for RSUs and $4.86 for DSUs granted during the three months ended March 31, 2023.

We measure the fair value of grants of PSUs using a monte carlo valuation. The weighted average fair value of the PSUs granted in the three months ended March 31, 2023 was $7.30 per share and will be expensed over a vesting period of three years. The final payout to holders of PSUs will be based upon the Company's total shareholder return relative to a peer group's performance measured at the end of each performance period.

In the three months ended March 31, 2023 and 2022, we recognized $0.8 million and $0.5 million, respectively, of stock-based compensation expense. The majority of the expense, $0.7 million and $0.4 million, respectively, was recorded in selling and administrative expense in the Condensed Consolidated Statements of Operations, with the remaining expense recorded in cost of goods sold.

As of March 31, 2023, the unrecognized compensation cost related to the unvested portion of all stock-based awards was approximately $14.0 million and is expected to be recognized over the remaining vesting period of the respective grants.